Geode Capital Management
PTHS

Geode Capital Management’s Pelthos Therapeutics PTHS Stock Holding History

Geode Capital Management’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$414K Sell
14,650
-640
-4% -$16.4K ﹤0.01% 3675
2026
Q1 		$321K Buy
15,290
+1,665
+12% +$39.5K ﹤0.01% 3749
2025
Q4 		$422K Buy
13,625
+3,295
+32% +$95K ﹤0.01% 3653
2025
Q3 		$289K Buy
10,330
+9,286
+889% +$225K ﹤0.01% 3809
2025
Q2 		$14.1K Buy
1,044
+37
+4% +$447 ﹤0.01% 4402
2025
Q1 		$14.3K Buy
+1,007
New +$17.2K ﹤0.01% 4406

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Geode Capital Management's PTHS Position: Q2 2026 in Review

Geode Capital Management reduced its Pelthos Therapeutics (PTHS) stake by 4.2% in Q2 2026, selling an estimated $16.4K and leaving 14,650 shares worth $414K. The position accounts for ﹤0.01% of the portfolio, ranked #3675.

Geode Capital Management first reported a position in PTHS in Q1 2025 and has held it in 6 quarters since. The position peaked at $422K in Q4 2025. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • Geode Capital Management held 14,650 shares of Pelthos Therapeutics worth $414K as of Q2 2026.
  • Geode Capital Management sold 640 Pelthos Therapeutics shares in Q2 2026, an estimated $16.4K.
  • Pelthos Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3675 holding.
  • Geode Capital Management first reported a position in Pelthos Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Geode Capital Management's Pelthos Therapeutics position peaked at $422K in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.